Is there an HIV prevention crisis? - IAVI. After marshaling great effort and achieving remarkable results in diagnosing HIV infections and providing life-saving
Graphic from the poster showing the evolution of guidelines in the 20 countries
Although dolutegravir has been recommended by the World Health Organization (WHO) as part of first-line HIV treatment for all adults since 2019, less than half of the African countries with the highest burden of HIV follow these guidelines, according to an analysis presented to the 11
th International AIDS Conference on HIV Science today.
With its high barrier to resistance, virological potency, superior side-effects profile and lower cost, the integrase inhibitor dolutegravir represents an improvement on previously recommended medications. Its first regulatory approval was in 2013, and in 2016 WHO recommended it as part of an alternate first line regimen.